Featured Research

from universities, journals, and other organizations

Can diabetes or lipid-lowering medications treat addiction?

Date:
April 6, 2011
Source:
Elsevier
Summary:
Thiazolidinediones (TZDs) are commonly prescribed to treat Type 2 diabetes, while fibrates are prescribed to modulate lipid levels in patients to help reduce the risk of cardiovascular disease. These drugs work by binding to peroxisome proliferator-activated receptors (PPARs). Another effect of TZDs and fibrates is to raise leptin levels, an effect that may reduce appetite.

Thiazolidinediones (TZDs) are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease. These drugs work by binding to peroxisome proliferator-activated receptors (PPARs), with TZDs reducing insulin resistance and lowering the levels of cytokines that promote inflammation, and fibrates reducing low-density lipoprotein (LDL) and triglyceride levels and increasing high-density lipoprotein (HDL) levels to help prevent the development of cardiovascular disease.

Another effect of TZDs and fibrates is to raise leptin levels, an effect that may reduce appetite. Recent studies also suggest that PPARs are expressed in the central nervous system, particularly in brain regions implicated in reward.

Two papers recently published in Biological Psychiatry now suggest that drugs that stimulate two different subclasses of PPARs, PPAR-a and PPAR-g, may play roles in the treatment of nicotine and alcohol addiction by acting in the brain.

The first study, by Mascia and colleagues, used a multi-pronged approach to demonstrate that nicotine's addictive effects can be counteracted by drugs that activate PPAR-α. In both rats and monkeys, these drugs reduced nicotine intake and relapse to nicotine seeking after a period of abstinence. They also prevented nicotine from altering electrical activity and neurochemical levels in addiction-related brain areas.

"Although our research involved highly selective experimental drugs, there are medications (fibrates) used clinically for the treatment of high cholesterol and triglyceride levels, which are selective PPAR-α ligands," further explained senior author Dr. Steven Goldberg. "Drugs that selectively affect PPAR-α receptors, possibly including fibrates, might provide a valuable new approach to the treatment of tobacco dependence in humans."

In the second study, Stopponi and colleagues used pioglitazone to evaluate its effects on alcohol drinking, relapse-like behavior, and withdrawal in rats. Pioglitazone activates PPAR-g and is an FDA-approved medication for the treatment of type 2 diabetes.

Corresponding author Dr. Roberto Ciccocioppo detailed their findings, "We demonstrated that activation of PPAR-g receptors by pioglitazone potently reduces alcohol consumption in a rat model of excessive drinking. We also found that pioglitazone abolishes alcohol craving elicited by exposure to stress and prevented the expression of somatic signs of alcohol withdrawal."

"As we learn more about the brain, we are seeing a growing number of examples where medications developed initially for purposes unrelated to psychiatry may have new and otherwise unexpected applications within psychiatry. In this case, the identification of neural PPARs in reward circuits suggested new roles for PPAR stimulators. These new data in animal models suggest that TZDs might be promising new agents in the fight against addiction," commented Dr. John Krystal, Editor of Biological Psychiatry.

It is important to note that these exciting initial findings are only the beginning steps in a line of research that will need to be undertaken before TZDs or fibrates could be used in a clinical setting to treat people with addictions.


Story Source:

The above story is based on materials provided by Elsevier. Note: Materials may be edited for content and length.


Journal References:

  1. Paola Mascia, Marco Pistis, Zuzana Justinova, Leigh V. Panlilio, Antonio Luchicchi, Salvatore Lecca, Maria Scherma, Walter Fratta, Paola Fadda, Chanel Barnes. Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. Biological Psychiatry, 2011; 69 (7): 633 DOI: 10.1016/j.biopsych.2010.07.009
  2. Serena Stopponi et al. Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking. Biological Psychiatry, Volume 69, Number 7 (April 1, 2011)

Cite This Page:

Elsevier. "Can diabetes or lipid-lowering medications treat addiction?." ScienceDaily. ScienceDaily, 6 April 2011. <www.sciencedaily.com/releases/2011/04/110405113018.htm>.
Elsevier. (2011, April 6). Can diabetes or lipid-lowering medications treat addiction?. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2011/04/110405113018.htm
Elsevier. "Can diabetes or lipid-lowering medications treat addiction?." ScienceDaily. www.sciencedaily.com/releases/2011/04/110405113018.htm (accessed October 2, 2014).

Share This



More Mind & Brain News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Stopping School Violence

Stopping School Violence

Ivanhoe (Oct. 1, 2014) A trauma doctor steps out of the hospital and into the classroom to teach kids how to calmly solve conflicts, avoiding a trip to the ER. Video provided by Ivanhoe
Powered by NewsLook.com
Pineal Cysts: Debilitating Pain

Pineal Cysts: Debilitating Pain

Ivanhoe (Oct. 1, 2014) A tiny cyst in the brain that can cause debilitating symptoms like chronic headaches and insomnia, and the doctor who performs the delicate surgery to remove them. Video provided by Ivanhoe
Powered by NewsLook.com
Burning Away Brain Tumors

Burning Away Brain Tumors

Ivanhoe (Oct. 1, 2014) Doctors are 'cooking' brain tumors. Hear how this new laser-heat procedure cuts down on recovery time. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins